- By FYH News Team
[ad_1]
Yemaachi Presents Findings on Mutation Profiles of Ghanaian Women with Breast Cancer at AORTIC 2023; Announces Formation of African Clinical Cancer Research Network
Results presented in collaboration with
Paemka Research Group at the University of Ghana represent largest
sequencing study of its kind conducted entirely in Africa to date;
Company’s cancer network will advance and scale precision oncology
research and collaborations across the continent
Yemaachi, the company dedicated to advancing precision oncology
research and care in Africa for the benefit of patients everywhere,
recently shared findings from a sequencing study in an abstract and
poster presentation at the 14th AORTIC International Conference on
Cancer in Africa.
The study, led by Dr. Lily Paemka, represents a collaboration
between Yemaachi and the Paemka Lab at the West African Centre for
Cell Biology of Infectious Pathogens (WACCBIP) of the University of
Ghana. The study profiled 106 samples of Ghanaian women with breast
cancer with whole exome sequencing to identify associated somatic
and driver mutations. Pathogenic or likely pathogenic variants in
known cancer genes including TP53, PIK3CA, BRCA1, NF1, and BRCA2
were found in 86% of samples. A novel BRCA1 variant was found at a
high VAF (75%) suggesting that it is an important variant for
future study.
“This work represents a growing effort, led by Yemaachi, to
characterise cancer development and progression in individuals of
African descent, who have traditionally been excluded from genomic
oncology studies and clinical trials,” said Yaw Bediako, CEO of
Yemaachi. “While this is currently the largest sequencing study of
its kind conducted entirely in Africa, our vision is to rapidly
scale this type of research to accelerate the development of
powerful and precise diagnostics and therapeutics that work in
diverse populations worldwide.”
In line with this vision, Yemaachi is announcing the formation
of a pan-African clinical cancer research network, AfriCAN. The
network will be focused on promoting pan-African cancer research,
led by African clinicians and scientists and performed on the
continent. AfriCAN will bring together clinicians, researchers, and
key opinion leaders in oncology across Africa to share knowledge,
promote collaboration and cross pollination of ideas, and highlight
excellence among members.
Yemaachi already has an extensive network of 24 academic
institutions, corporate partners, and hospitals across nine African
countries who will be founding network members. Among Yemaachi’s
clinical partners are institutions who see over 20,000 new cases of
cancer each year. To learn more about participating in the AfriCAN
network, potential members can get in touch at
partners@yemaachi.com.
About Yemaachi
Yemaachi is creating and harnessing the world’s most robust
cancer bio-database to develop the next generation of cancer
diagnostics and drugs that are effective in diverse populations.
Our mission is to save lives globally, while supporting the
well-being of communities that inspire and advance this work.
Yemaachi believes in a future where African genomic diversity,
insights, and expertise are an integral part of precision oncology
research, diagnostics, and therapeutics, for the benefit of
patients everywhere.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106505994/en/
Amy Puliafito
media@yemaachi.com
[ad_2]
Source link
Trending Topics
Features
- Drive Toolkit
Download and distribute powerful vaccination QI resources for your community.
- Health Champions
Sign up now to support health equity and sustainable health outcomes in your community.
- Cancer Early Detection
MCED tests use a simple blood draw to screen for many kinds of cancer at once.
- PR
FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.
- Medicare
Discover an honest look at our Medicare system.
- Alliance for Representative Clinical Trials
ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.
- Reducing Patient Risk
The single most important purpose of our healthcare system is to reduce patient risk for an acute event.
- Subash Kafle
- Jessica Wilson
- Jessica Wilson
